#lauruslabs #Q3marketupdates #Q3investorpresentations
Q3fy21/20 in crs
Rev 1288/730 ,up 76%
Ebidta 433/150
PAT 273/73 ,up 274%
EPS 5.1/1.4

Generic API growth 103% yoy
ARVs up 175% yoy
Generic FDF up 47%
Custom synthesis up 63% yoy
Onco API growth 36%

Generic APIs
ARV,Anti-DM,CVS,PPIs,Onco
Commercialized 60+ products
61 DMFs filed

Generic FDF
ARV,Anti-DM,CVS,PPIs,Onco
Filed 26 ANDAs with USFDA
9 final & 8 tentative approvals
Filed 12 dossiers in Canada, 9 in EU ,8 with WHO,2 in https://t.co/Q35cgK2hvy, 2 in India
Laurus Synthesis
CDMO services for Global pharma
Steroids,hormone mftg
Speciality ingredients in Nutraceuticals,dietary,cosmetics

Commercial scale mfg,clinical phase supplies,Analytics & research

API validation plannd in Unit 5
Optalmic initiated
LSPL-API validatn planned
Revenue breakup in crs
Q3fy21/20
Generic API 731/360
Generic FDF 430/292
Synthesis 127/78

Generic API
ARV 568/214
Onco 64/47
Other 99/99

Generic FDF 430/292

Entered in longterm partnership with leading generic player in EU for contract mfg

Synthesis CDMO 127/78 crs
Synthesis CDMO
Revenue from custom synthesis, strong growth 63% yoy
Total active projects in CDMO stood at 49 in Q3
Partnered Large global pharma & mid ,small biotech companies
Commercial supplies ongoing for 4 products
Revenue contribution
Fy20/fy16
Antiviral 82 /39
Onco API 8/7
Other API 3/ 11
Custom synthesis 7 /14
Generic FDF 0 / 29

9mnth fy21 / 20
ARV 39/38
ONCO 7/6
Other API 11/10
Custom synthesis 14/10
Generic FDF 29 /36
Completed acquisition of majority stake(72.55%) in Richcore Lifesciences Pvt ltd valued at 340 crs & 72.55% stake at 246.67 crs
Richcore Lifesciences to be renamed Laurus Bio Pvt Ltd
2 mfg facilities
1st has Fermentation capacity 10750 Lts while 2nd 1.8lk lts,available Mar21
Laurus Bio
Fast Growing Research Driven Bio-Mfg Company
Recombinant products - Animal origin free products for safer,viral free bio mfg
Precision Fermentation capabilities -scaleup expertise & large scale mfg capabilities
Strategic global partnerships for commercializn of product
Cumulative fillings
DMFs - 61
Patents filed 282
Patents approved 141

R&D spend
2016 - 85 cr (4.8%)
2020 - 134 (3.9%)

Outlook 2021 & beyond highlights :
Healthy order book for FY 21 & beyond in FDF CMO business with strategic partner in EU
Several new customers added with progs in various clinical phases

Generic FDF segment contributed ~36% in 9M FY 21 vs 2% FY19

Synthesis business to show gains with new customer additions in CDMO

Acq Aspen’s S.African Subsidiary, foothold in worlds' largest Generic ARV Mkt
Richcore acquisition to help enter high growth segments of AOF products, Enzymes & Biologics

Among top 5 in India in terms of Reactor capacities

All green field expansion turned Cash positive in FY20, near max utilization

Doubling our FDF capacity by FY22
Brown Field capex in existing sites to have shorter payback period and ROCE accretive

Acqd assets of an API Unit in Vizag to be used for backward integration ,pre clinical chemistry

Initiating green field expansion for all the divisions (API, FDF and Synthesis)

More from Finance

You May Also Like